CD274 and Miyoshi myopathy: However, no clinically meaningful results emerged from early clinical studies on PD-1/PD-L1 inhibitors as single agents in relapsed/refractory MM (RRMM) patients (9, 10); furthermore, FDA put on hold all the clinical trials using anti–PD-1/PD-L1 antibodies in combination with other therapeutic agents, as the IMiDs, in MM because of severe adverse events (https://www.fda.gov/Drugs/DrugSafety/ucm574305.htm).